Latest Videos |view all videos
John B. Kisiel, M.D., a gastroenterologist at Mayo Clinic's campus in Rochester, Minnesota, discusses a study that identified the source of cancer in patients' gastrointestinal tracts by analyzing DNA markers from tumors.
Herceptin has been touted as a wonder drug for women with HER2-positive breast cancer, an aggressive form of the disease that is fueled by excess production of the HER2 protein.
Researchers found that a combination of ibrutinib and chemotherapy reduced the risk of death or cancer progression by 80 percent in people with previously treated chronic lymphocytic leukemia.
Robert L. Foote, M.D., comments on findings of a new study by radiation oncologists at Mayo Clinic, comparing the world's literature on outcomes of proton beam therapy in the treatment of a variety of advanced head and neck cancers of the skull base.
Jakub James, M.D., demonstrates the operative technique of minimally invasive inguinal lymph node dissection in patients with melanoma. This video is intended for a surgical audience and is not intended to replace hands-on training.
Igor Frank, M.D., discusses surgical treatment options for people with prostate cancer.
Rory L. Smoot, M.D., describes treatment options and the specialized team of experts at Mayo Clinic who provide care for patients with cholangiocarcinoma.
R. Jeffrey Karnes, M.D., consultant and associate professor, Mayo Clinic, discusses treatment options for bladder cancer. The ailment can be subdivided into subcategories, and the treatments dramatically differ. Invasive treatments can ...
Jon Ebbert, M.D., of the Mayo Clinic Nicotine Dependence Center, on a study combining the smoking cessation medications varenicline and bupropion, compared with varenicline alone, that resulted in higher smoking abstinence rates.
Richard D. Hurt, M.D., director of Mayo Clinic's Nicotine Dependence Center, comments on a new report by the Surgeon General released Jan. 2014, The Health Consequences of Smoking — 50 Years of Progress, which highlights a half-century ...
Amplification of HER2, a known driver of some breast cancers, in a type of bladder cancer called micropapillary urothelial carcinoma (MPUC), has shown that the presence of HER2 amplification is associated with particularly aggressive tumors.
Alan P. Fields, Ph.D., and Dr. Monica Flynn Jacoby, professor of cancer studies at Mayo Clinic's campus in Florida, talk about the publication of his team's latest discovery.